A Potential Pharmacologic Treatment for OSA

A new study analyzed how a combination of atomoxetine and oxybutynin affects obstructive sleep apnea (OSA) severity. In this podcast, one of the study’s authors, Luigi Taranto-Montemurro, MD, from Harvard Medical School and Brigham and Women's Hospital, provides insight on his findings and what they mean for the future of pharmacotherapy for OSA.

Luigi Taranto-Montemurro, MD, is an instructor in medicine at Harvard Medical School. He is also an associate scientist in the Division of Sleep and Circadian Disorders, Department of Medicine, at Brigham and Women's Hospital.

Additional Resource:

Taranto-Montemurro L, Messineo L, Sands SA, et al. The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial. Am J Respir Crit Care Med. 2019;199(10). doi:10.1164/rccm.201808-1493OC.